The ‘Prolaris’ test, which is offered by Myriad Genetics Inc. (Salt Lake City, UT, USA), is a genomic test for predicting PCa aggressiveness in conjunction with clinical parameters such as Gleason Score and PSA [79]. The gene discussed is KLK3; the disease is posterior cortical atrophy.